Alnylam defends RNAi therapeutic efficacy following AstraZeneca trial failure

Alnylam is proactively defending its heart disease drug portfolio after AstraZeneca's Wainua failed to meet primary endpoints in a recent clinical trial. The market is questioning the viability of similar therapeutic mechanisms, though it remains unclear if the failure is specific to AstraZeneca's drug or indicative of broader class-wide efficacy issues.